Eurizon SLJ Capital Ltd Invests $10.13 Million in Agilent Technologies, Inc. $A

Key Points

• Eurizon SLJ Capital acquired 76,249 shares of Agilent Technologies worth approximately $10.13 million, making the stock its ninth-largest holding and 3.7% of its portfolio.
• Agilent reported quarterly EPS of $1.49 and revenue of $1.83 billion, exceeding analyst estimates, while revenue increased 10% year over year. The company guided for fiscal 2026 EPS of $6.00–$6.10.
• Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $160.24, compared with a recent price of $148.55.

Eurizon SLJ Capital Ltd acquired a new stake in Agilent Technologies, Inc. (NYSE:A - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 76,249 shares of the medical research company's stock, valued at approximately $10,128,000. Agilent Technologies comprises 3.7% of Eurizon SLJ Capital Ltd's investment portfolio, making the stock its 9th largest holding.

Several other hedge funds have also recently bought and sold shares of A. Norges Bank acquired a new stake in Agilent Technologies in the 4th quarter worth approximately $549,158,000. AQR Capital Management LLC lifted its stake in shares of Agilent Technologies by 424.1% in the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company's stock worth $240,956,000 after buying an additional 1,652,244 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Agilent Technologies by 132.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company's stock worth $277,807,000 after buying an additional 1,340,161 shares during the period. Balyasny Asset Management L.P. boosted its holdings in Agilent Technologies by 192.0% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,412,535 shares of the medical research company's stock valued at $192,204,000 after acquiring an additional 928,821 shares during the period. Finally, SG Americas Securities LLC grew its holdings in Agilent Technologies by 107.2% in the 1st quarter. SG Americas Securities LLC now owns 1,674,856 shares of the medical research company's stock valued at $190,900,000 after buying an additional 866,641 shares during the last quarter.

Agilent Technologies Trading Down 0.5%

Shares of A opened at $148.55 on Friday. The stock's fifty day simple moving average is $135.38 and its 200-day simple moving average is $125.56. The company has a quick ratio of 1.62, a current ratio of 2.10 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $41.95 billion, a PE ratio of 29.83, a price-to-earnings-growth ratio of 2.64 and a beta of 1.25. Agilent Technologies, Inc. has a 12-month low of $108.35 and a 12-month high of $160.27.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, May 27th. The medical research company reported $1.49 earnings per share for the quarter, topping the consensus estimate of $1.41 by $0.08. The firm had revenue of $1.83 billion during the quarter, compared to analysts' expectations of $1.80 billion. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The company's quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. As a group, research analysts predict that Agilent Technologies, Inc. will post 6.03 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 22nd. Shareholders of record on Tuesday, June 30th were paid a $0.255 dividend. The ex-dividend date of this dividend was Tuesday, June 30th. This represents a $1.02 dividend on an annualized basis and a yield of 0.7%. Agilent Technologies's dividend payout ratio (DPR) is presently 20.48%.

Wall Street Analyst Weigh In

A has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research report on Sunday, August 2nd. Barclays raised their target price on Agilent Technologies from $145.00 to $150.00 and gave the stock an "overweight" rating in a research report on Wednesday, June 24th. Wolfe Research reiterated a "hold" rating on shares of Agilent Technologies in a research report on Tuesday, June 2nd. HSBC dropped their price objective on Agilent Technologies from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Wednesday, June 3rd. Finally, Robert W. Baird boosted their target price on shares of Agilent Technologies from $155.00 to $156.00 and gave the company an "outperform" rating in a research note on Tuesday, May 26th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $160.24.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source